February 2020
Finish Cancer Through Research
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 130 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
New immunotherapy approaches for cutaneous squamous cell carcinoma
Photo credit: National Cancer Institute
Is checkpoint immunotherapy better with oncolytic viral therapy in patients with advanced cutaneous squamous cell carcinoma?

 A new phase 2 study open at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, will evaluate the curative potential of cemiplimab plus RP1, an investigational oncolytic virus, compared to cemiplimab monotherapy in patients with metastatic or locally-advanced cutaneous squamous cell carcinoma. 
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.